The results showed that SOX2 antibodies were more prevalent in patients with breast cancer (18.4%) than in healthy women (2.6%, P < 0.0001) and patients with benign breast disease (6.4%, P = 0.011). Here, SOX2 is linked to breast fibrocystic disease.